Cleararc Capital Lifted Its Xylem Com (XYL) Holding; Intercept Pharmaceuticals (ICPT) Has 0.99 Sentiment

June 19, 2017 - By Adrian Mccoy

Cleararc Capital Inc increased Xylem Inc Com (XYL) stake by 632.29% reported in 2016Q4 SEC filing. Cleararc Capital Inc acquired 31,014 shares as Xylem Inc Com (XYL)’s stock rose 8.81%. The Cleararc Capital Inc holds 35,919 shares with $1.78M value, up from 4,905 last quarter. Xylem Inc Com now has $9.70 billion valuation. The stock declined 0.33% or $0.18 reaching $53.87 on the news. About 99,432 shares traded. Xylem Inc (NYSE:XYL) has risen 20.76% since June 19, 2016 and is uptrending. It has outperformed by 4.06% the S&P500.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $3.07 billion. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. It currently has negative earnings. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Cleararc Capital Inc decreased Medtronic Plc (NYSE:MDT) stake by 22,111 shares to 41,818 valued at $2.98M in 2016Q4. It also reduced 3M Co Com (NYSE:MMM) stake by 2,737 shares and now owns 15,081 shares. Ishares Msci Japan Etf (EWJ) was reduced too.

Since February 27, 2017, it had 0 insider buys, and 2 selling transactions for $748,747 activity. Brannemo Tomas also sold $709,062 worth of Xylem Inc (NYSE:XYL) on Thursday, May 4.

Investors sentiment increased to 1.17 in Q4 2016. Its up 0.17, from 1 in 2016Q3. It is positive, as 40 investors sold XYL shares while 157 reduced holdings. 71 funds opened positions while 160 raised stakes. 152.74 million shares or 1.30% more from 150.78 million shares in 2016Q3 were reported. Braun Stacey holds 0.88% of its portfolio in Xylem Inc (NYSE:XYL) for 271,270 shares. Great Lakes Ltd Liability Corp reported 0.17% of its portfolio in Xylem Inc (NYSE:XYL). 7,671 were accumulated by Timber Hill Ltd. Allianz Asset Mgmt Ag reported 0.12% stake. Paradigm Fin Advsrs Ltd Liability Corporation invested 0.13% in Xylem Inc (NYSE:XYL). Meyer Handelman Commerce reported 21,400 shares stake. 22,867 are owned by Voloridge Invest Mgmt Ltd Liability Company. John G Ullman & Associate Inc has invested 0.42% in Xylem Inc (NYSE:XYL). Parametric Portfolio Associates Limited Liability Company has invested 0.02% in Xylem Inc (NYSE:XYL). Cipher Ltd Partnership reported 0.36% stake. Kornitzer Capital Mgmt Inc Ks has invested 0.05% in Xylem Inc (NYSE:XYL). 13,381 are owned by Dean Investment Ltd Liability Co. National Pension Serv invested in 623 shares or 0% of the stock. Rothschild Cap Ptnrs Limited Liability Company invested in 2.27% or 90,670 shares. Appleton Prtnrs Ma owns 0.1% invested in Xylem Inc (NYSE:XYL) for 9,916 shares.

Among 17 analysts covering Xylem (NYSE:XYL), 11 have Buy rating, 0 Sell and 6 Hold. Therefore 65% are positive. Xylem had 34 analyst reports since August 3, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, September 28 by Oppenheimer. The firm has “Equalweight” rating given on Monday, July 18 by Barclays Capital. On Monday, May 15 the stock rating was upgraded by Barclays Capital to “Overweight”. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, January 6. On Tuesday, April 5 the stock rating was upgraded by Sterne Agee CRT to “Buy”. The firm has “Outperform” rating by Boenning & Scattergood given on Friday, February 3. The firm has “Buy” rating given on Thursday, January 21 by Seaport Global. Cowen & Co maintained the stock with “Outperform” rating in Thursday, September 3 report. The stock of Xylem Inc (NYSE:XYL) has “Equal-Weight” rating given on Monday, October 5 by Barclays Capital. The firm earned “Buy” rating on Thursday, September 3 by Stifel Nicolaus.

About 112,695 shares traded. Intercept Pharmaceuticals Inc (ICPT) has declined 14.52% since June 19, 2016 and is downtrending. It has underperformed by 31.22% the S&P500.

Ghost Tree Capital Llc holds 1.83% of its portfolio in Intercept Pharmaceuticals Inc for 70,000 shares. Carmignac Gestion owns 2.02 million shares or 1.71% of their US portfolio. Moreover, Orbimed Advisors Llc has 1.55% invested in the company for 1.12 million shares. The Hong Kong-based Parametrica Management Ltd has invested 1.16% in the stock. Bb Biotech Ag, a Switzerland-based fund reported 255,719 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: